SCHEMBL862067

SCHEMBL862067

CS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(Cl)ccc2n1Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
CYP2C8 P10632 1/20 0.44
PTGDR2 Q9Y5Y4 6/20 0.44
PPARG P37231 2/20 0.42
RCE1 Q9Y256 1/20 0.42
MCL1 Q07820 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
ALOX12 P18054 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK8 P45983 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
CCR2 P41597 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862037 0.95 KMT2A (0.44) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862140 0.95 KMT2A (0.47) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL832125 0.94 KMT2A (0.45) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862357 0.93 KMT2A (0.44) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862156 0.93 KMT2A (0.42) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862375 0.93 KMT2A (0.44) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL10256439 0.92 KMT2A (0.42) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862277 0.92 KMT2A (0.45) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862324 0.92 KMT2A (0.42) KMT2ACYP2C8PTGDR2PPARGRCE1
SCHEMBL862086 0.92 KMT2A (0.42) KMT2ACYP2C8PTGDR2PPARGRCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 KMT2A 321/4885CYP2C8 847/4885PTGDR2 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.